- Market Capitalization, $K 3,882,563
- Shares Outstanding, K 30,890
- Annual Sales, $ 12,730 K
- Annual Income, $ -295,160 K
- 60-Month Beta 2.19
- Price/Sales 18.58
- Price/Cash Flow N/A
- Price/Book 5.52
|Period||Period Low||Period High||Performance|
| || |
+4.66 (+3.85%)since 01/21/20
| || |
+26.33 (+26.50%)since 11/21/19
| || |
-18.26 (-12.68%)since 02/21/19
GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.
InvestorsObserver issues critical PriceWatch Alerts for AMZN, BYND, FDX, GWPH, and TMUS.
In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $115.46, marking a -0.06% move from the previous day.
In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $113.64, marking a +1.81% move from the previous day.
GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $118.97, moving -0.13% from the previous trading session.
New Records Ahead of New Trade Deal and New Earnings Season
2020 is already a big year, we've got a presidential election, impeachment and Iranian incident. How's this going to effect our trading? It won't.
Here we discuss three best stocks in the emerging cannabis space.
|Gw Pharma ADR|
|Advisorshares Pure Cannabis ETF|
|Pharmaceutical Vaneck ETF|
|Nasdaq Biotechnology Ishares ETF|
|Bldrs Europe Select ADR Index Fund Invesco|
|Bldrs Developed Markets 100 ADR Index Fund Inves|